Host: The Japanese Society of Toxicology
Name : The 49th Annual Meeting of the Japanese Society of Toxicology
Date : June 30, 2022 - July 02, 2022
The global outbreak of the novel coronavirus disease (COVID-19) is still ongoing. Many patients with severe COVID-19 are complicated by acute respiratory distress syndrome (ARDS) and have a poor prognosis. Therefore, developments of biomarkers for early diagnosis of COVID-19 progression are needed. In this study, we compared and evaluated their predictive performances of five lung injury-related biomarkers: lung surfactant protein-D (SP-D), the sialylated carbohydrate antigen KL-6, the sepsis marker presepsin (P-SEP), and the novel interstitial pneumonia biomarker candidates, kallistatin and stratifin (SFN).
We measured concentrations of these proteins in serum samples collected serially during hospitalization from patients of mild disease (mild and moderate cases without further deterioration) or patients who developed to severe COVID-19 pneumonia (severe and critical cases requiring oxygen administration and invasive ventilation). This analysis showed that SFN and P-SEP were elevated with the onset of severe or critical symptoms in COVID-19 patients and decreased with symptom improvement. Changes in serum levels of both proteins were distinctly earlier than those in SP-D and KL-6, also known as biomarkers for pulmonary fibrosis, and even peripheral oxygen saturation (SpO2) values, with significantly higher values several days before patient onset severe disease. These results were reproduced in an independent cohort. SFN and P-SEP may be useful prognostic biomarkers for COVID-19 severity.
